- PS01 Session 1 - Clinical Indications
- PS02 Session 2 - New Clinical Data and Trial Pipeline
- PS03 Session 3 - Next-Gen CAR-T Therapy
- PS04 Session 4 - CAR-T in Oncology
- PS06 Session 6 - New CAR-T Indications
- PS07 Session 7 - CAR-T: New Standard of Care in Lymphoma?
- PS08 Session 08 - Clinical management
PS01 Session 1 - Clinical Indications
Moderators: Thomas Cluzeau (France) & Claire Roddie (United Kingdom)
Summary of the presentation with more than 20 direct links to the papers mentioned in the presentation DOWNLOAD
CONCLUSIONS
- The introduction of CART cell therapy has revolutionized th of patients with B-Cell NHL
- Excellent results in phase II pivotal prospective clinical trials
- Real world data in both EU and US replicate results of PCT
- Identification of prognostic factors
- New indications (diseases, early stages) will be coming soon
CONCLUSIONS
- CLL among the first diseases treated with CAR-T, but still no approved product
- CAR-T can overcome the T cell defects seen in this disease and lead in some cases to durable responses
- Immune modulators to enhance T cell function are being explored and most developed with lbrutinib
- NK and other cell types being explored
Conclusions
- The first CART cell product targeting BCMA was approved in the US/EU /Abecma
- ide-cel) in 2021 and a second BCMA CART cell product (cilta-cel) will be approved for r/r MM probably in 2022
- CART cell therapy can induce ORR up to 100% and a CR beyond 80% in patients with r/r MM (with a median of 6 lines of prior therapy) and a PFS of > 2 years
In The Future:
- CART therapy will potentially become a part of the first-line therapy for ultra/high risk patients
- CART therapy will challenge ASCT in TE NDMM
- CART therapy for earlier lines of therapy also in non-transplant eligible patients (low rate of grade >3 CRS/ICANS)
Summary of the presentation with more than 20 direct links to the papers mentioned in the presentation DOWNLOAD
----------------------------------------------------------------------------------------------------------------------------
This year's meeting covered a wide range of topics. In turn, VJHemOnc did interviews on the following topics such as deep science, translational, clinical and commercial development in the field of CAR-T. See these posts on the VJHemOnc events page
PS02 Session 2 - New Clinical Data and Trial Pipeline
PS03 Session 3 - Next-Gen CAR-T Therapy
Moderators: Álvaro Urbano Ispizua (Spain) & Chiara Bonini (Italy)